0.01Open0.01Pre Close0 Volume221 Open Interest10.00Strike Price0.00Turnover162.60%IV49.21%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0052Delta0.0027Gamma1967.00Leverage Ratio-0.0034Theta0.0000Rho-10.31Eff Leverage0.0005Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet